China Resources Sanjiu plans to invest up to RMB 100 bn in wealth management

China Resources Sanjiu Medical & Pharmaceutical announced its intention to invest up to RMB 100 billion of its own funds in bank wealth management products and structured deposits. This follows the imminent expiration of its current wealth management product authorization. The company and its subsidiaries will invest in fixed-income non-guaranteed floating income wealth management products (risk rating R2 or below) offered by banks and their wealth management subsidiaries, excluding Zhuhai China Resources Bank. Structured deposits are also included.

The authorized investment period extends from shareholder approval until October 9, 2026. Funds can be rolled over, with the transaction amount at any given time, including reinvested proceeds, not exceeding RMB 100 billion. Each individual product will have a maximum duration of six months. The investment aims to enhance capital efficiency and improve the return on the company's existing idle funds.

This proposal has been approved by the board of directors on September 17, 2025, and will be submitted for shareholder approval. The company emphasizes its commitment to "standardized operations, risk prevention, prudent investment, and value preservation and appreciation," ensuring that daily operations and capital security are not impacted while seeking investment returns for shareholders.